FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1917991231> ?p ?o ?g. }

• W1917991231 abstract "Several erythropoiesis-stimulating agents (ESAs) are available for treating anaemia in people with chronic kidney disease (CKD). Their relative efficacy (preventing blood transfusions and reducing fatigue and breathlessness) and safety (mortality and cardiovascular events) are unclear due to the limited power of head-to-head studies.To compare the efficacy and safety of ESAs (epoetin alfa, epoetin beta, darbepoetin alfa, or methoxy polyethylene glycol-epoetin beta, and biosimilar ESAs, against each other, placebo, or no treatment) to treat anaemia in adults with CKD.We searched the Cochrane Renal Group's Specialised Register to 11 February 2014 through contact with the Trials' Search Co-ordinator using search terms relevant to this review.Randomised controlled trials (RCTs) that included a comparison of an ESA (epoetin alfa, epoetin beta, darbepoetin alfa, methoxy polyethylene glycol-epoetin beta, or biosimilar ESA) with another ESA, placebo or no treatment in adults with CKD and that reported prespecified patient-relevant outcomes were considered for inclusion.Two independent authors screened the search results and extracted data. Data synthesis was performed by random-effects pairwise meta-analysis and network meta-analysis. We assessed for heterogeneity and inconsistency within meta-analyses using standard techniques and planned subgroup and meta-regression to explore for sources of heterogeneity or inconsistency. We assessed our confidence in treatment estimates for the primary outcomes within network meta-analysis (preventing blood transfusions and all-cause mortality) according to adapted GRADE methodology as very low, low, moderate, or high.We identified 56 eligible studies involving 15,596 adults with CKD. Risks of bias in the included studies was generally high or unclear for more than half of studies in all of the risk of bias domains we assessed; no study was low risk for allocation concealment, blinding of outcome assessment and attrition from follow-up. In network analyses, there was moderate to low confidence that epoetin alfa (OR 0.18, 95% CI 0.05 to 0.59), epoetin beta (OR 0.09, 95% CI 0.02 to 0.38), darbepoetin alfa (OR 0.17, 95% CI 0.05 to 0.57), and methoxy polyethylene glycol-epoetin beta (OR 0.15, 95% CI 0.03 to 0.70) prevented blood transfusions compared to placebo. In very low quality evidence, biosimilar ESA therapy was possibly no better than placebo for preventing blood transfusions (OR 0.27, 95% CI 0.05 to 1.47) with considerable imprecision in estimated effects. We could not discern whether all ESAs were similar or different in their effects on preventing blood transfusions and our confidence in the comparative effectiveness of different ESAs was generally very low. Similarly, the comparative effects of ESAs compared with another ESA, placebo or no treatment on all-cause mortality were imprecise.All proprietary ESAs increased the odds of hypertension compared to placebo (epoetin alfa OR 2.31, 95% CI 1.27 to 4.23; epoetin beta OR 2.57, 95% CI 1.23 to 5.39; darbepoetin alfa OR 1.83, 95% CI 1.05 to 3.21; methoxy polyethylene glycol-epoetin beta OR 1.96, 95% CI 0.98 to 3.92), while the effect of biosimilar ESAs on developing hypertension was less certain (OR 1.18, 95% CI 0.47 to 2.99). Our confidence in the comparative effects of ESAs on hypertension was low due to considerable imprecision in treatment estimates. The comparative effects of all ESAs on cardiovascular mortality, myocardial infarction (MI), stroke, and vascular access thrombosis were uncertain and network analyses for major cardiovascular events, end-stage kidney disease (ESKD), fatigue and breathlessness were not possible. Effects of ESAs on fatigue were described heterogeneously in the available studies in ways that were not useable for analyses.In the CKD setting, there is currently insufficient evidence to suggest the superiority of any ESA formulation based on available safety and efficacy data. Directly comparative data for the effectiveness of different ESA formulations based on patient-centred outcomes (such as quality of life, fatigue, and functional status) are sparse and poorly reported and current research studies are unable to inform care. All proprietary ESAs (epoetin alfa, epoetin beta, darbepoetin alfa, and methoxy polyethylene glycol-epoetin beta) prevent blood transfusions but information for biosimilar ESAs is less conclusive. Comparative treatment effects of different ESA formulations on other patient-important outcomes such as survival, MI, stroke, breathlessness and fatigue are very uncertain.For consumers, clinicians and funders, considerations such as drug cost and availability and preferences for dosing frequency might be considered as the basis for individualising anaemia care due to lack of data for comparative differences in clinical benefits and harms." @default.
• W1917991231 created "2016-06-24" @default.
• W1917991231 creator A5009624452 @default.
• W1917991231 creator A5018429053 @default.
• W1917991231 creator A5034928512 @default.
• W1917991231 creator A5035896202 @default.
• W1917991231 creator A5038938109 @default.
• W1917991231 creator A5080193257 @default.
• W1917991231 creator A5086167151 @default.
• W1917991231 creator A5088217633 @default.
• W1917991231 date "2014-12-08" @default.
• W1917991231 modified "2023-10-17" @default.
• W1917991231 title "Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis" @default.
• W1917991231 cites W122269675 @default.
• W1917991231 cites W137395437 @default.
• W1917991231 cites W145334081 @default.
• W1917991231 cites W1521352376 @default.
• W1917991231 cites W1546710001 @default.
• W1917991231 cites W1576226830 @default.
• W1917991231 cites W1578634351 @default.
• W1917991231 cites W1593260599 @default.
• W1917991231 cites W1596829678 @default.
• W1917991231 cites W1600783343 @default.
• W1917991231 cites W1606337231 @default.
• W1917991231 cites W186227245 @default.
• W1917991231 cites W1908561690 @default.
• W1917991231 cites W1917991231 @default.
• W1917991231 cites W1960181941 @default.
• W1917991231 cites W1963824520 @default.
• W1917991231 cites W1964852190 @default.
• W1917991231 cites W1965332918 @default.
• W1917991231 cites W1966025583 @default.
• W1917991231 cites W1966355257 @default.
• W1917991231 cites W1970157737 @default.
• W1917991231 cites W1971945597 @default.
• W1917991231 cites W1975279686 @default.
• W1917991231 cites W1977489157 @default.
• W1917991231 cites W1978005541 @default.
• W1917991231 cites W1979147335 @default.
• W1917991231 cites W1979507915 @default.
• W1917991231 cites W1982268114 @default.
• W1917991231 cites W1983874550 @default.
• W1917991231 cites W1987189111 @default.
• W1917991231 cites W1987811659 @default.
• W1917991231 cites W1988698998 @default.
• W1917991231 cites W1989268721 @default.
• W1917991231 cites W1989661749 @default.
• W1917991231 cites W1991301759 @default.
• W1917991231 cites W1998943227 @default.
• W1917991231 cites W2001920176 @default.
• W1917991231 cites W2002569322 @default.
• W1917991231 cites W200286333 @default.
• W1917991231 cites W2003478281 @default.
• W1917991231 cites W2003993648 @default.
• W1917991231 cites W2005947177 @default.
• W1917991231 cites W2005973637 @default.
• W1917991231 cites W2006185464 @default.
• W1917991231 cites W2008213781 @default.
• W1917991231 cites W2008668845 @default.
• W1917991231 cites W2010699829 @default.
• W1917991231 cites W2016422315 @default.
• W1917991231 cites W2016504951 @default.
• W1917991231 cites W2017165606 @default.
• W1917991231 cites W2017564728 @default.
• W1917991231 cites W2018814956 @default.
• W1917991231 cites W2022826689 @default.
• W1917991231 cites W2023146075 @default.
• W1917991231 cites W2024074211 @default.
• W1917991231 cites W2025749817 @default.
• W1917991231 cites W2026851794 @default.
• W1917991231 cites W2029568661 @default.
• W1917991231 cites W2029774820 @default.
• W1917991231 cites W2030554743 @default.
• W1917991231 cites W2031418395 @default.
• W1917991231 cites W2031947293 @default.
• W1917991231 cites W2033803279 @default.
• W1917991231 cites W2034795608 @default.
• W1917991231 cites W2037593179 @default.
• W1917991231 cites W2040029744 @default.
• W1917991231 cites W2040421189 @default.
• W1917991231 cites W2042385910 @default.
• W1917991231 cites W2046224330 @default.
• W1917991231 cites W2046506563 @default.
• W1917991231 cites W2046615795 @default.
• W1917991231 cites W2047816645 @default.
• W1917991231 cites W2049666202 @default.
• W1917991231 cites W2049843297 @default.
• W1917991231 cites W2053443809 @default.
• W1917991231 cites W2058123619 @default.
• W1917991231 cites W2058907838 @default.
• W1917991231 cites W2060380118 @default.
• W1917991231 cites W2062252820 @default.
• W1917991231 cites W2063244779 @default.
• W1917991231 cites W2064114564 @default.
• W1917991231 cites W2065055449 @default.
• W1917991231 cites W2067988311 @default.
• W1917991231 cites W2068697451 @default.
• W1917991231 cites W2070558085 @default.
• W1917991231 cites W2070734091 @default.
• W1917991231 cites W2074147400 @default.

• next